Skip to main content
Premium Trial:

Request an Annual Quote

Cancellation of GE/Abbott Dx Deal Topped Most-Read GenomeWeb Daily News Stories Last Week

NEW YORK (GenomeWeb News) - What are GenomeWeb News subscribers reading? Below are the five most-read articles for the five-day period ended Friday, July 13.
 
1. GE Healthcare and Abbott Scuttle $8B Deal for Diagnostics Units (from July 12)
 
2. Despite Looming NIH Cash Crunch, Genomic Nonprofit CEOs Enjoy Soaring Salaries (from July 10)
 
3. Roche Acquires Alnylam Lab to Build RNAi Excellence Center; Buys Stake and Forges Alliance (from July 9)
 
4. Roche, Hungry for Ventana, Challenges State Law; Plans to Pursue Shareholders (from July 11)
 
5. GE Healthcare's Q2 Revenue, Profit Slide (from July 13)
The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.